Study of NTB003 for thyroid eye disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new medication (NTB003) for people with thyroid eye disease (TED), a condition that can cause bulging eyes, double vision, and discomfort. It aims to see if the treatment is safe and helps reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You weigh between 40 kg (about 88 lbs) and 100 kg (about 220 lbs).
- You have been diagnosed with active thyroid eye disease (symptoms started within the past year) or chronic thyroid eye disease (symptoms for over a year) with moderate-to-severe symptoms like bulging eyes, double vision, or eyelid problems.
- You do not need emergency eye surgery and are not planning any corrective eye surgery or radiation therapy during the study.
- Your thyroid condition is under control (or only mildly over- or under-active).
- If you could have children, you must agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (KHN939) for people with moderate-to-severe active thyroid eye disease. If you qualify, the study may help reduce bulging eyes and double vision.
This early-stage trial tests a new drug called IBI3031 to treat active thyroid eye disease (TED), a condition where the immune system attacks muscles and tissue around the eyes, causing swelling, bulging, and sometimes double vision. The study aims to see if this drug can reduce inflammation and improve symptoms.
This study tests an investigational drug, KHN939, for people with moderate-to-severe inactive thyroid eye disease (also called Graves' eye disease). The goal is to see if the drug can improve symptoms such as bulging eyes and double vision. Participation lasts for several months and involves regular check-ups.
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This trial tests two doses of an oral medication (linsitinib) for people with active, moderate-to-severe thyroid eye disease who were in a previous study and didn't improve enough or had their bulging come back. It aims to see if continuing treatment can help with eye bulging and other symptoms.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.